So far, 515 patients have been genotyped for HLA-B*1502 which is associated with risk of developing Stevens-Johnson syndrome following use of carbamazepine (Chen et al., 2011), in addition to 318 patients genotyped for TPMT in patients that may be treated with thiopurines. Here, TPMT is linked to Stevens-Johnson syndrome.